Isotonische Kochsalz-Lösung Eifelfango (Sodium Chloride)

Sodium chloride in the solution provides an osmotic force that draws water into the extracellular space, expanding plasma volume. The chloride ion helps maintain electrical neutrality, while the sodium component restores normal serum sodium concentrations, supporting vascular tone and overall fluid homeostasis.

The dosage of Isotonische Kochsalz-Lösung Eifelfango is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and fluid‑loss assessment. No fixed regimen is provided here; the prescriber sets the appropriate volume and infusion rate for each individual case.

Safety data for use in pregnancy or while breastfeeding are limited. The decision to use the product in these populations should be made by the treating physician after weighing potential benefits against any possible risks to the mother and infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Isotonische Kochsalz-Lösung Eifelfango is comparable to other 0.9% sodium chloride injection products in terms of composition and clinical use. Differences may lie in manufacturing standards, packaging, and regulatory approvals. GNH India ensures the product meets EU quality specifications and is supplied under GDP‑compliant conditions.

Store the solution at ambient temperature, preferably below 25 °C, in its original sealed container. Protect it from direct sunlight, excessive heat and moisture. Do not freeze the product. Before use, inspect the container for any signs of damage or contamination and follow aseptic techniques during preparation.

The solution is administered intravenously. It can be given as a direct infusion or added to an IV fluid bag, depending on the clinical requirement. Administration should follow aseptic technique, with infusion rates adjusted according to the patient’s cardiovascular and renal status, as directed by the healthcare professional.

Serious risks include severe hypernatremia, which can cause neurological symptoms, and pulmonary edema, which may impair breathing. Both conditions arise from excessive sodium or fluid administration, especially in patients with compromised cardiac or renal function. Prompt monitoring of serum electrolytes and fluid status helps mitigate these risks.

Patients with pre‑existing hypernatremia, uncontrolled fluid overload, severe congestive heart failure, or renal failure requiring strict fluid restriction should avoid this product unless a physician determines that the benefits outweigh the risks. Contraindications are based on individual clinical assessment.